Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.lpm.2010.12.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interplay between creeping fat and gut microbiota: A brand-new perspective on fecal microbiota transplantation in Crohn's disease.
World J Gastroenterol
January 2025
Department of Gastroenterology, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, Anhui Province, China.
Inflammatory bowel disease, particularly Crohn's disease (CD), has been linked to modifications in mesenteric adipose tissue (MAT) and the phenomenon known as "creeping fat" (CrF). The presence of CrF is believed to serve as a predictor for early clinical recurrence following surgical intervention in patients with CD. Notably, the incorporation of the mesentery during ileocolic resection for CD has been correlated with a decrease in surgical recurrence, indicating the significant role of MAT in the pathogenesis of CD.
View Article and Find Full Text PDFExploring perinatal mesenchymal stromal cells as a potential therapeutic strategy for rheumatoid arthritis.
Heliyon
January 2025
Department of Life Science and Public Health, Università Cattolica Del Sacro Cuore, Rome, Italy.
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by inflammation in the synovial tissue, driven by aberrant activation of both the innate and adaptive immune systems, which can lead to irreversible disability. Despite the increasing therapeutic approaches for RA, only a low percentage of patients achieve sustained disease remission, and the persistence of immune dysregulation is likely responsible for disease recurrence once remission is attained. Cell therapy is an attractive, wide-spectrum strategy to modulate inflammation, and mesenchymal stromal cells (MSC) derived from perinatal tissues provide valuable tools for their use in regenerative medicine, mainly due to their immunomodulatory properties.
View Article and Find Full Text PDFSpontaneous Resolution and Recurrence of Aseptic Splenic Abscesses in a Patient With Newly Diagnosed Crohn's Disease.
Cureus
December 2024
Internal Medicine - Gastroenterology, Faculty of Medical Sciences, Lebanese University, Beirut, LBN.
Aseptic splenic abscesses are rare in the early phases of Crohn's disease and are typically reported in patients with longstanding illness or uncontrolled symptoms despite medical treatment. We present a case of recurrent aseptic splenic abscesses in a young man newly diagnosed with Crohn's disease, whose illness remained well-controlled. This unique case raises questions regarding the spontaneous resolution of aseptic splenic abscesses without steroid therapy and their recurrence without acute Crohn's disease flare-ups.
View Article and Find Full Text PDFThe role of intestinal ultrasound with colour Doppler in predicting the response to biologic therapy in inflammatory bowel disease patients.
Prz Gastroenterol
November 2023
Department of Internal Medicine, Hepato-gastroenterology Unit, Faculty of Medicine, Assiut University, Assiut, Egypt.
Introduction: Inflammatory bowel disease patients are exposed to frequent procedures and hospital admissions as well as recurrent need for radiological examinations with a high risk of exposure to radiation and contrast.
Aim: Our objective was to evaluate the role of a combination of both intestinal ultrasound (IUS) and colour Doppler with different parameters for monitoring changes in inflammation over time and to reveal their potential role in the assessment of response to biologic therapy in inflammatory bowel disease (IBD) patients.
Material And Methods: Before the induction of biological therapy, IUS together with colour Doppler of the intestine was conducted.
Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis.
Kidney Int Rep
January 2025
Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Introduction: Complement 3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) have high risks for disease recurrence and allograft loss in transplant kidneys. Pegcetacoplan (targeted complement 3 [C3]/C3b inhibitor) may prevent excessive deposition of C3 and complement 5 [C5] breakdown products and associated renal damage.
Methods: NOBLE (NCT04572854) is a prospective, phase 2, multicenter, open-label, randomized controlled trial evaluating the efficacy and safety of pegcetacoplan in posttransplant patients with recurrent C3G or IC-MPGN.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!